Home » Posts tagged 'pharmaceutical' (Page 2)
Tag Archives: pharmaceutical
#ORPH Open Orphan – Inside the quarantine lab where Irish company infects humans with Covid
Step into the foyer of the Whitechapel Hotel in London and it seems no different from any other business. But venture further in, and it becomes clear that something very strange is going on in this former textile factory.
Biohazard signs on each floor warn observers not to enter. Next to the double beds in the bright and modern en-suite rooms are white trolleys containing swabs, vials, gloves and other medical paraphernalia. Peepholes on the doors are not there so that guests can look out into the corridor.
Instead, they are reversed for safety reasons.
This former hotel, a victim of the Covid pandemic, has been transformed into a 19-bed quarantine facility used to house volunteers taking part in human challenge studies – specialist clinical trials where people are infected with a virus or bacteria to see how they respond to experimental vaccines or treatments.
Link here for the article
Link here for the full Sunday Telegraph article
Poolbeg Pharma #POLB – RNA sequencing ahead of AI analysis programme
RNA sequencing ahead of pioneering AI analysis programme
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics (‘Eurofins’), to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus (RSV) disease progression samples from human viral challenge studies.
This deep sequencing work is a key step leading to Poolbeg commencing Artificial Intelligence (AI) analysis of its RSV data and will mean that it then has full immunological datasets for RSV, as well as influenza, which are ready to use with AI platforms to identify drug targets and products for influenza and RSV indications. The Company already has RNA sequencing data for influenza. This data is unique as it covers the full disease cycle and presents significant opportunities to unlock insights into these diseases which will magnify the power of the AI analysis.
The project with Eurofins is expected to be completed by the end of 2021 and will involve next generation RNA sequencing of RSV transcriptomics, or disease progression data, which enables the tracking of the biology of immune responses in molecular detail during infection.
Sequencing of the samples will be tailored for incorporation into AI algorithms which will be the first time that human challenge trial immune data has been analysed using AI, unlocking unique insights from the rich dataset that Poolbeg will translate into additional pipeline products which will be progressed using its capital light clinical structure.
RSV is a contagious virus that affects the respiratory tract of children and at-risk older adults; in severe cases, it can cause pneumonia and other life-threatening breathing difficulties. RSV is a significant public health threat and is one of the leading causes of hospitalisation to at-risk older adults. There is currently no vaccine on the market for RSV.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“This is an exciting step in our AI data analysis programme. The deep genetic analysis of RSV progression will be key information to feed into AI drug and target discovery tools. We already have similar data for influenza so we will now have complete discovery datasets for both influenza and RSV.
Our AI analysis will be breaking new ground in data-driven drug discovery as it will be the first time that human challenge trial immune data is used in this way. Having the sequencing specially tailored to work with AI platforms will enable us to discover potential new drug candidates for both diseases in a quicker and more cost-effective way.”
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+353 (0) 1 644 0007 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson Richard Chambers, Sunila de Silva (ECM)
|
+44 (0) 20 7220 0500 |
|
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell, Oscair McGrath
|
+44 (0) 207 614 5900 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 poolbeg@instinctif.com |
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to licence or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from Open Orphan plc , an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.
For more information, please go to www.poolbegpharma.com
About Eurofins Genomic s
Eurofins Genomics is a global leader in genomic products and services .Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company’s strength is its extensive customer base and high-quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit www.eurofinsgenomics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
#ANA Ananda Developments Plc – Research Facility Construction Update
Ananda, the AQSE-listed medical cannabis company creating UK-based operations to grow and provide carbon neutral, consistent, pharmaceutical quality medical cannabis for the UK and international markets, provides the following update on the construction of its research facility.
Since the Company’s update on 6 September 2021, works have continued on schedule at the medical cannabis research growing facility being developed in the UK by DJT Plants Limited (“DJT Plants”), the Company’s 50% owned subsidiary.
As previously announced the facility footprint has been increased. To provide further detail to shareholders, it now incorporates:
- a dedicated growing room for female plants (which produce the resin secreting flowers used for medicinal cannabis)
- a dedicated growing room for male plants (grown to pollinate the female plants)
- a dedicated plant nursery
- a dedicated room for mother plants (to guarantee genetic consistency of each generation of plants)
- laboratory space (for trimming plants, analysing characteristics and test work)
- enlarged work rooms
The facility is also being constructed to allow for thorough cleaning and to accommodate appropriate work flows and movement of plants through the work rooms. These are requirements for Good Manufacturing Practices (“GMP”) certification, which will be applied for in due course. The facility construction management team (supplied by Ananda’s partner JE Piccaver & Co (Gedney Marsh) Limited (“JEPCO”)) is well versed in all aspects of high plant care standards, as they are required in the salad leaf industry where JEPCO operates as a large-scale speciality grower. Salad leaves are not cooked before being consumed, so the team is very familiar with the required levels of hygiene, work-flow management and deep cleaning. JEPCO operates to Red Tractor standards, which were established in 2000 and which have grown to become the UK’s biggest farm and food standards scheme, covering all aspects of food safety, traceability and environmental protection. JEPCO is also accredited under Global GAP (the Global Partnership for Safe and Sustainable Agriculture) and is a Selected Grower under the Marks & Spencer Field to Fork programme.
DJT Plants holds a licence from the Home Office of the UK Government to grow >0.2% THC cannabis for research purposes.
The Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
| PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking YELLOW JERSEY PR |
+44 (0)20 7469 0930
+44 (0) 7585 953 660 |
Alan Green CEO of Brand Communications talks about: i3 Energy #I3E Cranswick #CWK Tertiary Minerals #TYM Open Orphan #ORPH
Open Orphan Plc (ORPH) Directorate Changes
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director.
David has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin. David has an excellent combination of experience having worked in larger product focussed pharmaceutical companies and also in turning around smaller pharmaceutical companies. For example, he and his colleagues transformed AGI Therapeutics before selling it to Vidara Therapeutics which in turn was acquired by Horizon Therapeutics plc, a company with a current market capitalisation of $4.5 billion.
David also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company’s successful IPO on Nasdaq. In addition, David also held roles in Elan Corporation and KPMG.
With David joining the Board and following the completion of the Company’s acquisition of Open Orphan DAC, Tony Richardson has stepped down from the Board with effect from today. The Company would like to thank him for his service as a Director.
Professor Brendan Buckley, Chairman, Open Orphan, commented:
“We are delighted that David is joining the Board of Open Orphan. He has extensive experience in the orphan drug market and we are looking forward to having David work closely with management going forward as we seek to rapidly grow the company.”
The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies and paragraph (g) of Schedule Two of the Euronext Growth Rules for Companies:
Full name: David George Kelly
Age: 58
Current Directorships / Partnerships: Iterum Therapeutics plc, Iterum Therapeutics International Limited, Andromeda Biotech Limited, Horizon Pharma Israel Holding Corp. Limited, Horizon Pharma Investment Limited, Horizon Pharma Ireland Limited.
Past Directorships / Partnerships (past 5 years): Horizon Pharma GMBH, Horizon Pharma Rheumatology Limited, Horizon Pharma Switzerland GMBH, Horizon Pharma Finance S.A.R.L, Horizon Pharma Services Limited, Horizon Pharma Finance Limited, Horizon Pharma Holdings 2 Limited, Hyperion Therapeutics Ireland Operating Limited, Hyperion Therapeutics Ireland Holdings Limited, Horizon Pharma Treasury Limited, Horizon Pharma Holdings Limited, Horizon Pharma Capital Limited, Hyperion Therapeutics International Operating Limited, Hyperion Therapeutics International Holdings Limited, Horizon Therapeutics plc, Horizon Pharma Aon Limited, Horizon Pharma Trí Limited, Horizon Pharma Dó Limited.
Enquiries:
Open Orphan Plc Tel: +353 (0)1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.